ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

8 links3 made here, not in the record9 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govMade here
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT04495153CAN-2409 Plus Prodrug WithStandard of Care ImmuneCheckpoint Inhibitor forStage III/IV NSCLCCandel Therapeutics, Inc.Phase 2 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 5 · ClinicalTrials.gov record · Version of 2026-11-05Version of 2026-11-05CONDITIONSCarcinoma, Non-Small-Cell L…The registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionLung NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedDRUGSAglatimagene besadenovecIntervention entry›Nov 18 · Rule based · TestedTestedValacyclovirIntervention entry›Nov 18 · Rule based · BackgroundBackgroundINT007009Entry “Chemotherapy”, read by our nam…›Nov 18 · Rule based · BackgroundBackgroundPembrolizumabMade here · Found by reading; no entr…›Nov 16 · Claude Opus 5.5 · Background · optionBackground · optionNivolumabMade here · Found by reading; no entr…›Nov 16 · Claude Opus 5.5 · Background · optionBackground · optionDurvalumabMade here · Found by reading; no entr…›Nov 16 · Claude Opus 5.5 · Background · optionBackground · option

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Pembrolizumab

Made here1 judgment on this link
NCT04495153gives it, found by reading the recordPembrolizumabDefined by Claude Opus 5.5Nov 16 (day only)
Role in the study, from the registry to what was judged
RegistryNot in the recordno intervention entry names it
→judged

All judgments on this study

WhenLinkJudgeDecisionState
Nov 5The record itselfClinicalTrials.gov recordVersion of 2026-11-05Record change
Nov 14Carcinoma, Non-Small-Cell LungRule based · condition-kind ruleFinest filed termCurrent
Nov 14Lung NeoplasmsRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 16Pembrolizumabmade hereClaude Opus 5.5Background · optionCurrent
Nov 16Nivolumabmade hereClaude Opus 5.5Background · optionCurrent
Nov 16Durvalumabmade hereClaude Opus 5.5Background · optionCurrent
Nov 18Aglatimagene besadenovecRule based · role ruleTestedCurrent
Nov 18ValacyclovirRule based · role ruleBackgroundCurrent
Nov 18INT007009Rule based · role ruleBackgroundCurrent
As of nowCarcinoma, Non-Small-Cell LungRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.